Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H14O6 |
Molecular Weight | 218.2039 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)OCC(COC(C)=O)OC(C)=O
InChI
InChIKey=URAYPUMNDPQOKB-UHFFFAOYSA-N
InChI=1S/C9H14O6/c1-6(10)13-4-9(15-8(3)12)5-14-7(2)11/h9H,4-5H2,1-3H3
Molecular Formula | C9H14O6 |
Molecular Weight | 218.2039 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/14555416Curator's Comment: Description was created using several sources including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050808lbl.pdf; http://www.ncbi.nlm.nih.gov/pubmed/?term=20800682; http://www.inchem.org/documents/sids/sids/102761.pdf;
Sources: http://www.ncbi.nlm.nih.gov/pubmed/14555416
Curator's Comment: Description was created using several sources including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050808lbl.pdf; http://www.ncbi.nlm.nih.gov/pubmed/?term=20800682; http://www.inchem.org/documents/sids/sids/102761.pdf;
Triacetin, also known as Glyceryl Triacetate, is a cosmetic biocide, plasticizer, and solvent in cosmetic formulations, at concentrations ranging from 0.8% to 4.0%. It is a commonly used carrier for flavors and fragrances. Triacetin was affirmed as a generally recognized as safe (GRAS) human food ingredient by the Food and Drug Administration (FDA). It is used as an inactive ingredient additive in some drug formulations. It has been used as a plasticizer in the tests of acrylic polymer films for drug delivery. Triacetin is not toxic to animals. However, in one study, it caused erythema, slight edema, alopecia, and desquamation, and did cause some irritation in rabbit eyes. Concentration of triacetin in consumer products is in the range of about 0.005-2 % for cosmetics, and has been reported to be as high as 15-33 % for one specific antifungal drug.
CNS Activity
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Inactive ingredient | Bupropion Approved UseBupropion hydrochloride extended-release tablets (XL) is indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of the immediate-release formulation of Bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with MDD. The efficacy of the sustained-release formulation of Bupropion in the maintenance treatment of MDD was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to Bupropion in an 8-week study of acute treatment. Launch Date1985 |
Doses
Dose | Population | Adverse events |
---|---|---|
50 % single, topical Studied dose Dose: 50 % Route: topical Route: single Dose: 50 % Sources: |
healthy, adult n = 20 Health Status: healthy Age Group: adult Population Size: 20 Sources: |
Other AEs: Skin irritation... Other AEs: Skin irritation (grade 1) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Skin irritation | grade 1 | 50 % single, topical Studied dose Dose: 50 % Route: topical Route: single Dose: 50 % Sources: |
healthy, adult n = 20 Health Status: healthy Age Group: adult Population Size: 20 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Preparation and characterization of spray-dried oxidized cellulose microparticles. | 2001 Aug |
|
Arterial wall neovascularization induced by glycerol. | 2001 Oct |
|
Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. | 2001 Sep 11 |
|
Calibration standardization algorithm for partial least-squares regression: application to the determination of physiological levels of glucose by near-infrared spectroscopy. | 2002 Aug 15 |
|
Halogen derivatives of m-phenylene(carbeno)nitrene: a switch in ground-state multiplicity. | 2002 Aug 9 |
|
Starch acetate--a novel film-forming polymer for pharmaceutical coatings. | 2002 Jan |
|
Distinction between esterases and lipases: a kinetic study with vinyl esters and TAG. | 2002 Jul |
|
Dynamics of therapeutic ultrasound contrast agents. | 2002 Jun |
|
Dynamics and fragmentation of thick-shelled microbubbles. | 2002 Oct |
|
Final report on the safety assessment of triacetin. | 2003 |
|
Characterization of a quaternary liquid system improving the bioavailability of poorly water soluble drugs. | 2003 Jul 15 |
|
Multivariate calibration standardization across instruments for the determination of glucose by Fourier transform near-infrared spectrometry. | 2003 Nov 1 |
|
Design of a mechanical-tunable filter spectrometer for noninvasive glucose measurement. | 2004 May 1 |
|
Raman spectroscopy investigation of various saturated monoacid triglycerides. | 2005 Apr |
|
The novel formulation design of self-emulsifying drug delivery systems (SEDDS) type O/W microemulsion II: stable gastrointestinal absorption of a poorly water soluble new compound, ER-1258 in bile-fistula rats. | 2005 Aug |
|
Cancer mortality in a cohort of asbestos textile workers. | 2005 Feb 14 |
|
Transitions induced by solubilized fat into reverse hexagonal mesophases. | 2005 Jun 25 |
|
Use of taste-masking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals. | 2006 Dec 29 |
|
Poly lactic acid based injectable delivery systems for controlled release of a model protein, lysozyme. | 2006 Feb |
|
Stable bioavailability of cyclosporin A, regardless of food intake, from soft gelatin capsules containing a new self-nanoemulsifying formulation. | 2006 May |
|
Microemulsions as transdermal drug delivery vehicles. | 2006 Nov 16 |
|
Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems. | 2006 Oct 10 |
|
Design and evaluation of a self-adhesive naproxen-loaded film prepared from a nanoparticle dispersion. | 2006 Sep-Oct |
|
Abstracts of papers presented at the 2007 pittsburgh conference. | 2007 |
|
Controlled release multiparticulate beads coated with starch acetate: material characterization, and identification of critical formulation and process variables. | 2007 |
|
Spectral simulation methodology for calibration transfer of near-infrared spectra. | 2007 Apr |
|
Nanoemulsions as vehicles for transdermal delivery of aceclofenac. | 2007 Dec 14 |
|
Effect of salts and plasticizers on stability of shellac film. | 2007 Feb 7 |
|
Kinetic model of 1,3-specific triacylglycerols alcoholysis catalyzed by lipases. | 2007 Jan 20 |
|
Monitoring of dissolution induced changes in film coat composition by 1H NMR spectroscopy and SEM. | 2007 Jun 4 |
|
Gelatin-based microcarriers as embryonic stem cell delivery system in bone tissue engineering: an in-vitro study. | 2007 Mar |
|
Design and characterization of an adhesive matrix based on a poly(ethyl acrylate, methyl methacrylate). | 2008 |
|
Formulation design of taste-masked particles, including famotidine, for an oral fast-disintegrating dosage form. | 2008 Apr |
|
Transdermal patch incorporating salbutamol sulphate: In vitro and clinical characterization. | 2008 Aug |
|
Template enhanced activity of lipase accommodated in siliceous mesocellular foams. | 2008 Aug 8 |
|
In vitro and in vivo transdermal studies of atenolol using iontophoresis. | 2008 Jan-Feb |
|
Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. | 2008 Jul 9 |
|
A potential high-throughput method for the determination of lipase activity by potentiometric flow injection titrations. | 2008 Mar 3 |
|
Determination of the composition of acetylglycerol mixtures by (1)H NMR followed by GC investigation. | 2008 Nov 15 |
|
Influence of plasticizers on the stability and release of a prodrug of Delta(9)-tetrahydrocannabinol incorporated in poly (ethylene oxide) matrices. | 2008 Oct |
|
Viability and permeability across Caco-2 cells of CBZ solubilized in fully dilutable microemulsions. | 2008 Oct 1 |
|
Hookah (Shisha, Narghile) Smoking and Environmental Tobacco Smoke (ETS). A critical review of the relevant literature and the public health consequences. | 2009 Feb |
|
Digital filtering and model updating methods for improving the robustness of near-infrared multivariate calibrations. | 2009 Feb |
|
Spectral simulation protocol for extending the lifetime of near-infrared multivariate calibrations. | 2009 Feb 1 |
|
Evaluation of the mechanical properties and drug release of cross-linked Eudragit films containing metronidazole. | 2009 Jul 6 |
|
Thermostable lipases from the extreme thermophilic anaerobic bacteria Thermoanaerobacter thermohydrosulfuricus SOL1 and Caldanaerobacter subterraneus subsp. tengcongensis. | 2009 Sep |
|
A glycerol-free process to produce biodiesel by supercritical methyl acetate technology: an optimization study via Response Surface Methodology. | 2010 Feb |
|
Eudragit-S, Eudragit-L and cellulose acetate phthalate coated polysaccharide tablets for colonic targeted delivery of azathioprine. | 2010 Jul-Aug |
|
Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease. | 2010 Jun |
|
Wavelet analysis used for spectral background removal in the determination of glucose from near-infrared single-beam spectra. | 2010 Nov 29 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: http://www.inchem.org/documents/sids/sids/102761.pdf
Curator's Comment: When triacetin was incubated with the sacs of rats everted intestine, the glyceride entered the epithelial cells and was completely hydrolyzed to free glycerol and acetic acid. Triacetin released 307 ± 11 umoles of acetate. With increasing concentrations of glyceride (5, 10 and 15 mM), the amount of acetate released increased linearly up to about a total amount of 300 umoles of acetate released.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:48:24 GMT 2023
by
admin
on
Sat Dec 16 15:48:24 GMT 2023
|
Record UNII |
XHX3C3X673
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1697
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
||
|
JECFA EVALUATION |
INS-1518
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-1518
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
||
|
CFR |
21 CFR 175.320
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
||
|
CFR |
21 CFR 184.1901
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
XHX3C3X673
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
XHX3C3X673
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
C82268
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
TRIACETIN
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
3624
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
SUB11249MIG
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
102-76-1
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
731
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
836
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
m11021
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | Merck Index | ||
|
1675007
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
203-051-9
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
9661
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
4796
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
10756
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1489254
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
DTXSID3026691
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
100000077489
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
5541
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY | |||
|
585
Created by
admin on Sat Dec 16 15:48:25 GMT 2023 , Edited by admin on Sat Dec 16 15:48:25 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Triacetine (ug/cigarette)
Canadian = 23.1 SD(15.6)
Imported = 36.3 SD(9.3)
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|